The Drugs Controller General of India (DCGI) approved 26 new drug formulations for marketing in the country during Jan-June period of 2004.The drugs approved include Cabergoline 1 mg/2 mg/4 mg tablets for Parkinson's disease and Oxybutynine E.R. tablets for neurogenic bladder disorder.

The other drugs approved are Rabeprazole Sodium Injection 20 mg / vial for Gastric and Deudonal Ulcers & GERD, Alfuzosin E.R. Tablets (10 mg) for BPH, Tiagabine HCl tablet (2/ 4 /12 /16 mg), an anti-epileptic, Racecadotril Sachet (10 mg/30 mg), an anti-diarrhoeal, Ibandronic Acid Inj ( 1 mg/ml) for anti-Cancer, Tacrolimus Capsule (0.5mg/1mg/5 mg) for organ rejection, Cefdinir Dispersible tablet (125mg), an antibiotic, Linezolid (600 mg) Tablet for Osteomyelitis in adults, FDC of Gatifloxacin 0.3% + Dexamethasone Phos. 0.1% w/w Eye drops for post-operative inflammatory and bacterial infection of eyes, Cefprozil Dispersible Tablet (125 mg/ 250 mg) an anti-biotic, Divalproex Sodium E.R. Tablets (750mg/1000 mg) an anti-Epileptic, Lithium Carbonate ER (450mg) tablet for anti-depression, Nimesulide Injection 75mg/ml.f or short-term treatment of post-operative pain. FDC of Esomeprazole 20 mg/40 mg + Domperidone 30 mg SR Capsule for GERD, Aceclofenac (100 mg) + Paracetamol(500 mg) for acute painful condition in adults, Neotame, a sweetening agent, Trolamine Cream (0.67%) for tropical use, Nitazoxanide an Anti-Diarrhoeal, Dutasteride for BPH, Gefitinib an anti-cancer drug, Imidapril an anti-hypertensive, Adefovir Dipivoxil an Anti-Viral (Hepatitis-B), Etoricoxib a NSAID and Diacerein for Osteoarthritis treatment.